We combined behavioral testing with brain imaging using 99m Tc-HMPAO (Amersham Health), to identify CNS structures reflecting alterations in pain perception in the streptozotocin (STZ) model of Type 1 diabetes. We induced diabetic hyperglycemia (blood glucose >300 mg/dl) by injecting male Sprague-Dawley rats with STZ (45 mg/kg i.p.). Four weeks after STZ, diabetic rats exhibited behaviors indicative of neuropathic pain (hypersensitivity thermal stimuli) and this hypersensitivity persisted for up to six weeks. Imaging data in STZ-diabetic rats revealed significant increases in the activation of brain regions involved in pain processing after six weeks duration of diabetes. These regions included secondary somatosensory cortex, ventrobasal thalamic nuclei and the basolateral amygdala. In contrast, the activation in habenular nuclei and the midbrain periaqueductal gray were markedly decreased in STZ rats. These data suggest that pain in diabetic neuropathy may be due in part to hyperactivity in somatosensory structures coupled with a concurrent deactivation of structures mediating antinociception.Diabetes mellitus (DM) is one of the most common chronic medical problems affecting millions of people world-wide (Spruce, et al., 2003), and is the most prevalent cause of neuropathy in the United States, affecting more than 14 million persons (Mokdad, et al., 2000). A frequent complication of diabetes is unremitting pain and a reduced quality of life (Benbow, et al., 1994). Patients with DM may experience a variety of aberrant sensations including spontaneous pain and hypersensitivity to mechanical or thermal stimuli, followed by the long term paradoxical loss of stimulus-evoked sensation (Benbow, et al., 1994). Other symptoms encountered are an inability to detect heat and cold, cutaneous hyperaesthesia, loss of vibration sensation, and paradoxically, the loss of pain perception. Although numerous studies have indicated that DM produces various metabolic and morphological changes in the peripheral nervous system, and have suggested that these changes may be associated with neuropathic symptoms (Sima and Sugimoto, 1999), the pathophysiology of neuropathic pain in diabetes remains unclear.